Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company’s pipeline contains its most advanced candidates, PRAX-114 and PRAX-944, which are in Phase 2 development for […]